National Comprehensive Cancer Network® (NCCN®) Recommended Ferric derisomaltose is recommended by the NCCN as a treatment option for iron-deficiency anemia in certain patients. Details below

One infusion of FDA-approved Monoferric can provide a full course of IV iron therapy in as little as 20 minutes1,*

Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:

  • Who have intolerance to oral iron or have had unsatisfactory response to oral iron
  • Who have non-hemodialysis-dependent chronic kidney disease (NDD-CKD)

*Intravenous infusion of 1000 mg over at least 20 minutes. Repeat dose if IDA reoccurs. Please refer to the Dosing and Administration page for additional details.

National Comprehensive Cancer Network® (NCCN®) Recommended Ferric derisomaltose is recommended by the NCCN as a treatment option for iron-deficiency anemia in certain patients. Details below

Hear from Dr Huzefa Bahrain, a Hematologist-Oncologist

Dr Bahrain explains why he uses Monoferric to treat IDA.

I’m Dr. Huzefa Bahrain, welcome to Monoferric Moments.

I practice hematology and oncology in Baltimore. We operate an erythropoiesis center where we treat a wide variety of patients with various iron deficiency anemia etiologies. They can range from bariatric surgery patients to heart failure, to pregnancy.

Monoferric is an intravenous iron replacement therapy that can be given in just 1 single dose, delivering 1000 milligrams.

In my experience, we find that for most patients, just 1 dose of 1000 milligrams of Monoferric is sufficient to replace iron stores. If iron deficiency anemia reoccurs, a repeat dose would be necessary.

I use Monoferric in my practice because of its overall combination of 1-dose administration, efficacy, tolerability, and patient support services.

For more information, explore Monoferric.com

Have questions about Monoferric?

Sign up to contact a representative.

Contact us

Innovative matrix controls bioavailable iron release

Monoferric is FDA approved for one infusion in as little as 20 minutes that delivers a slow and controlled release of bioavailable iron for patients with IDA.1,2,a

aRepeat dose if IDA reoccurs.

Learn about controlled iron release

Artist rendition

Pharmacosmos has over 60 years’ experience researching and developing innovative treatments

Monoferric was introduced more than 10 years ago as Monofer® in the EU. Monofer is available in more than 55 countries and more than 68 million doses have been administered (as defined by the WHO definition of 100-mg doses).

1 dose of Monoferric vs up to 5 doses of iron sucrose

The safety and efficacy of Monoferric for treatment of IDA were evaluated in two randomized, open-label, noninferiority, actively controlled clinical trials performed in a total of 3050 patients with IDA of different etiologies.3,4

See the results

1000 mg IV iron in a single infusion in ≥20 minutesb

Monoferric offers iron infusion in one dose in a single 1000-mg vial for patients weighing 50 kg or more.1 Monoferric is FDA approved to administer 1000 mg in ≥20 minutes.

bRepeat dose if IDA reoccurs.

See Dosing & Administration

Ferric derisomaltose (Monoferric) is a recommended parenteral iron preparation by the NCCN Guidelines®c

cReferenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) for Hematopoietic Growth Factors, V.3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed February 9, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org.

Monoferric Patient Solutions® delivers multifaceted support to help address IDA treatment needs

Pharmacosmos has a wide range of tools and resources available for you and your patients, including:

  • Benefits verification
  • Claims and appeals assistance
  • Sample letters of appeal and/or medical necessity
  • Prior authorization assistance
  • Financial assistance
  • In-person reimbursement support
  • Help navigating step therapy and legislative hurdles including Step Therapy Exception Requests
Learn more about how Pharmacosmos Therapeutics can help your patients access Monoferric.
Efficacy|Mean Change in Hb Levels

References: 1. Monoferric (ferric derisomaltose) Prescribing Information; Pharmacosmos Therapeutics Inc., Morristown, NJ: 2022. 2. Jahn MR, Andreasen HB, Fütterer S, et al. Eur J Pharm Biopharm. 2011;78(3):480-491. 3. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. Am J Hematol. 2019;94(9):1007-1014. 4. Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Nephrol Dial Transplant. 2021;36(1):111-120.

IMPORTANT SAFETY INFORMATION

Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.

INDICATIONS

Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:

  • who have intolerance to oral iron or have had unsatisfactory response to oral iron
  • who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.

Iron Overload

Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload.

ADVERSE REACTIONS

Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferric. Adverse reactions related to treatment and reported by ≥1% of the treated patients were nausea (1.2%) and rash (1%). Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferric group. Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferric-treated patients in Trials 1 & 2.

To report adverse events, please contact Pharmacosmos at 1-888-828-0655. You may also contact the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see Full Prescribing Information.